Search Results - "ENGBER, Thomas M."

Refine Results
  1. 1

    Small Molecule SARM1 Inhibitors Recapitulate the SARM1−/− Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate by Hughes, Robert O., Bosanac, Todd, Mao, Xianrong, Engber, Thomas M., DiAntonio, Aaron, Milbrandt, Jeffrey, Devraj, Rajesh, Krauss, Raul

    Published in Cell reports (Cambridge) (05-01-2021)
    “…Axonal degeneration is responsible for disease progression and accumulation of disability in many neurodegenerative conditions. The axonal degenerative process…”
    Get full text
    Journal Article
  2. 2

    cADPR is a gene dosage-sensitive biomarker of SARM1 activity in healthy, compromised, and degenerating axons by Sasaki, Yo, Engber, Thomas M., Hughes, Robert O., Figley, Matthew D., Wu, Tong, Bosanac, Todd, Devraj, Rajesh, Milbrandt, Jeffrey, Krauss, Raul, DiAntonio, Aaron

    Published in Experimental neurology (01-07-2020)
    “…SARM1 is the central executioner of pathological axon degeneration, promoting axonal demise in response to axotomy, traumatic brain injury, and neurotoxic…”
    Get full text
    Journal Article
  3. 3

    Studies to Assess the Utility of Serum Neurofilament Light Chain as a Biomarker in Chemotherapy-Induced Peripheral Neuropathy by Cavaletti, Guido, Pizzamiglio, Chiara, Man, Albert, Engber, Thomas M, Comi, Cristoforo, Wilbraham, Darren

    Published in Cancers (23-08-2023)
    “…Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and disabling dose-limiting toxicities of chemotherapy. We report here the results…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    Effect of combined treatment with methylprednisolone and soluble Nogo-66 receptor after rat spinal cord injury by Ji, Benxiu, Li, Mingwei, Budel, Stephane, Pepinsky, R. Blake, Walus, Lee, Engber, Thomas M., Strittmatter, Stephen M., Relton, Jane K.

    Published in The European journal of neuroscience (01-08-2005)
    “…Methylprednisolone (MP) is a synthetic glucocorticoid used for the treatment of spinal cord injury (SCI). Soluble Nogo‐66 receptor (NgR) ectodomain is a novel…”
    Get full text
    Journal Article
  7. 7
  8. 8

    D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons by GERFEN, C. R, ENGBER, T. M, MAHAN, L. C, SUSEL, Z, CHASE, T. N, MONSMA, F. J, SIBLEY, D. R

    “…The striatum, which is the major component of the basal ganglia in the brain, is regulated in part by dopaminergic input from the substantia nigra. Severe…”
    Get full text
    Journal Article
  9. 9

    Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration by Papa, S M, Engber, T M, Kask, A M, Chase, T N

    Published in Brain research (31-10-1994)
    “…The pathogenesis of the motor fluctuations that complicate levodopa treatment of most parkinsonian patients remains uncertain. To evaluate the contribution of…”
    Get more information
    Journal Article
  10. 10
  11. 11

    Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil by Engber, Thomas M, Koury, Elizabeth J, Dennis, Shelley A, Miller, Matthew S, Contreras, Patricia C, Bhat, Ratan V

    Published in Neuroscience letters (30-01-1998)
    “…We examined the neuronal targets in the rat brain for the novel wakefulness-promoting agent modafinil and for amphetamine using c-Fos immunohistochemistry…”
    Get full text
    Journal Article
  12. 12

    NMDA receptor blockade reverses motor response alterations induced by levodopa by Engber, T M, Papa, S M, Boldry, R C, Chase, T N

    Published in Neuroreport (20-12-1994)
    “…Motor fluctuations that ultimately complicate the response of most parkinsonian patients to levodopa therapy might represent a form of behavioral or neuronal…”
    Get more information
    Journal Article
  13. 13

    Motor response complications and the function of striatal efferent systems by Chase, Thomas N, Mouradian, Maral M, Engber, Thomas M

    Published in Neurology (01-12-1993)
    “…Motor response complications eventually appear in most patients with advanced Parkinsonʼs disease being treated with levodopa. The interval between onset of…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Substance P increases release of acetylcholine in the dorsal striatum of freely moving rats by Anderson, J J, Chase, T N, Engber, T M

    Published in Brain research (01-10-1993)
    “…Little is known about the role that neuropeptides such as substance P play in cell-to-cell interactions in the striatum. The effect of locally perfused…”
    Get more information
    Journal Article
  16. 16

    GABAA and GABAB receptors differentially regulate striatal acetylcholine release in vivo by Anderson, J J, Kuo, S, Chase, T N, Engber, T M

    Published in Neuroscience letters (01-10-1993)
    “…Microdialysis was used to study the effects of selective GABAergic agents on striatal acetylcholine (ACh) release in awake, freely moving rats. Local perfusion…”
    Get more information
    Journal Article
  17. 17

    Identification of insulin-like growth factor binding protein-2 as a biochemical surrogate marker for the in vivo effects of recombinant human insulin-like growth factor-1 in mice by Bhat, R V, Engber, T M, Zhu, Y, Miller, M S, Contreras, P C

    “…Recent studies indicate that a daily s.c. injection of 1 mg/kg of recombinant human insulin-like growth factor-1 (rhIGF-1) for 17 days is efficacious in…”
    Get more information
    Journal Article
  18. 18

    Region‐Specific Targets of p42/p44MAPK Signaling in Rat Brain by Bhat, Ratan V., Engber, Thomas M., Finn, James P., Koury, Elizabeth J., Contreras, Patricia C., Miller, Matthew S., Dionne, Craig A., Walton, Kevin M.

    Published in Journal of neurochemistry (01-02-1998)
    “…: In vitro studies indicate that p42/p44MAPK phosphorylate both nuclear and cytoplasmic proteins. However, the functional targets of p42/p44MAPK activation in…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Synthesis of alkyne derivatives of a novel triazolopyrazine as A 2A adenosine receptor antagonists by Yao, Gang, Haque, Serajul, Sha, Li, Kumaravel, Gnanasambandam, Wang, Joy, Engber, Thomas M., Whalley, Eric T., Conlon, Patrick R., Chang, Hexi, Kiesman, William F., Petter, Russell C.

    Published in Bioorganic & medicinal chemistry letters (01-02-2005)
    “…[Display omitted] A novel [1,2,4]triazolo[1,5- a]pyrazine core was synthesized and coupled with terminal acetylenes. The structure–activity relationship of the…”
    Get full text
    Journal Article